Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

HGS to use Dyax technology to screen for peptides

Executive Summary

Dyax will apply its phage display method of drug discovery in a collaboration to identify and optimize leads for Human Genome Sciences' therapeutic targets. Dyax may also use its phage--viruses that attack bacteria and can be engineered to express peptides--to develop high-throughput screens for HGS and to purify its development candidates and drugs.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies